Literature DB >> 24376967

Stevens Johnson Syndrome in a patient undergoing gynaecological brachytherapy: An association or an incident?

Miguel Reis Ferreira1, Ana Amado1, Marília Jorge1, Isabel Monteiro Grillo1.   

Abstract

BACKGROUND: Stevens Johnson Syndrome and Erythema Multiforme are hypersensitivity skin reactions generally arising in the context of multiple causes. Radiation therapy is considered to be one of these causes, although most reports are hindered by concomitant medications. AIM: The aim of this paper was to present a case of Stevens Johnson Syndrome arising in a patient undergoing gynaecological brachytherapy with an unusual presentation. CASE: We describe a case of a 56-year-old woman with endometrial cancer undergoing adjuvant gynaecological radiotherapy. While undergoing a gynaecological brachytherapy boost, she developed bilateral conjunctivitis that progressed to oral mucositis and pruritic erythema with sloughing of the skin on her arms and legs but not the torso or irradiated fields (namely the vaginal mucosa).
CONCLUSION: This case illustrates the association of RT/SJS; however, it also raises the question of patients undergoing RT being more susceptible to SJS as opposed to a direct cause of the disease.

Entities:  

Keywords:  Brachytherapy; Endometrial cancer; Erythema Multiforme; Radiotherapy; Stevens Johnson; Stevens Johnson Syndrome

Year:  2011        PMID: 24376967      PMCID: PMC3863256          DOI: 10.1016/j.rpor.2011.02.002

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  16 in total

1.  Two cases of Stevens-Johnson syndrome: toxic epidermal necrolysis possibly induced by amifostine during radiotherapy.

Authors:  I Lale Atahan; E Ozyar; S Sahin; F Yildiz; B Yalçin; A Karaduman
Journal:  Br J Dermatol       Date:  2000-11       Impact factor: 9.302

2.  Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient receiving concurrent radiation and gemcitabine.

Authors:  Karen R Sommers; Kevin M Kong; Dang T Bui; John P Fruehauf; Randall F Holcombe
Journal:  Anticancer Drugs       Date:  2003-09       Impact factor: 2.248

Review 3.  Increased risk of erythema multiforme major with combination anticonvulsant and radiation therapies.

Authors:  G Micali; K Linthicum; N Han; D P West
Journal:  Pharmacotherapy       Date:  1999-02       Impact factor: 4.705

4.  Erythema multiforme and Stevens-Johnson syndrome following radiotherapy.

Authors:  Tadamasa Yoshitake; Katsumasa Nakamura; Yoshiyuki Shioyama; Tomonari Sasaki; Saiji Ooga; Madoka Abe; Yusuke Urashima; Kazunori Urabe; Hiromi Terashima; Hiroshi Honda
Journal:  Radiat Med       Date:  2007-01-25

5.  Stevens-Johnson syndrome in a patient receiving anticonvulsant therapy during cranial irradiation.

Authors:  Y Eralp; A Aydiner; F Taş; P Saip; E Topuz
Journal:  Am J Clin Oncol       Date:  2001-08       Impact factor: 2.339

6.  Allergic skin reactions to anticonvulsant medications in patients receiving cranial radiation therapy.

Authors:  H J Mamon; P Y Wen; A C Burns; J S Loeffler
Journal:  Epilepsia       Date:  1999-03       Impact factor: 5.864

7.  Pharmacovigilance study of alendronate in England.

Authors:  Pipasha N Biswas; Lynda V Wilton; Saad A W Shakir
Journal:  Osteoporos Int       Date:  2003-04-23       Impact factor: 4.507

8.  Toxic epidermal necrolysis in Stevens--Johnson syndrome.

Authors:  D Assaad; L From; D Ricciatti; H Shapero
Journal:  Can Med Assoc J       Date:  1978-01-21       Impact factor: 8.262

9.  Irradiated fields spared Stevens-Johnson syndrome in a patient undergoing radiotherapy for bone metastases.

Authors:  Daniela Musio; Elisabetta Parisi; Francesco Dionisi; Giuseppe Parisi; Rossella Caiazzo; Nadia Bulzonetti; Miriam Lichtner; Nicola Raffetto; Vincenzo Vullo; Enzo Banelli
Journal:  Jpn J Radiol       Date:  2009-03-12       Impact factor: 2.374

10.  Stevens-Johnson Syndrome and toxic epidermal necrolysis overlap due to oral temozolomide and cranial radiotherapy.

Authors:  Nilendu Sarma
Journal:  Am J Clin Dermatol       Date:  2009       Impact factor: 7.403

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.